After one of the most dramatic sell-offs in recent ASX healthcare history, Cochlear Ltd (ASX: COH) shares may finally be showing signs of life.
The hearing implant leader remains down around 60% year to date, but it has quietly staged a comeback in recent weeks, climbing 8.5% over the past month. At the time of writing, Cochlear shares trade at $104.45.
So, is this modest recovery the start of something bigger?
Here are three reasons investors may want to consider buying the healthcare stock in June.
The bad news may already be priced in
It’s worth remembering just how brutal April was for shareholders.
Most of the pain arrived on 22 April following the release of a decidedly unwelcome trading update.
Cochlear shares closed down 40.7% in a single session after the company reported falling demand for its implants in developed markets. Management also flagged cancellations and delivery delays in the Middle East due to the ongoing conflict.
The update forced the company to slash its FY2026 underlying net profit guidance to between $290 million and $330 million, down from its prior guidance range of $435 million to $460 million.
The downgrade shocked investors. But after such a severe reset in expectations, the market may have already priced in much of the near-term weakness.
Cochlear remains the industry leader
While earnings expectations have changed, Cochlear’s competitive position has not.
The company still commands roughly 50% of the global cochlear implant market, making it the clear industry leader.
Even more importantly, the long-term growth opportunity for Cochlear shares remains enormous. The addressable market exceeds six million patients in developed markets alone, yet penetration sits at only around 3%.
Over more than four decades, Cochlear has invested heavily in research and development, building a product moat that competitors have struggled to replicate.
With ageing populations, growing awareness of hearing loss, and continued adoption of implantable hearing technology, the long-term demand outlook remains compelling.
Analysts and management see a brighter future
Broker sentiment has become increasingly constructive following the sell-off.
Both Jarden and Wilsons Advisory believe the market reaction has been excessive, with each seeing upside of more than 60% in Cochlear shares over the next 12 months.
Management also continues to argue that the recent volume weakness is temporary rather than structural.
CEO Dig Howitt stated the following in the company’s April trading update:
The clinical need for cochlear implants continues to grow, particularly for the adult and seniors segment. Cochlear implants are also associated with a lower incidence of dementia, with dementia rates lower than in hearing aid users and comparable to those with normal hearing.
Those comments highlight an important point. The factors that drove Cochlear’s long-term growth story before April’s shock downgrade remain firmly in place today.
If demand stabilises and delivery disruptions ease, investors buying Cochlear shares after the sell-off could be well positioned to benefit from a recovery in both earnings expectations and market sentiment.
The post 3 reasons to buy Cochlear shares in June appeared first on The Motley Fool Australia.
Should you invest $1,000 in Cochlear right now?
Before you buy Cochlear shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cochlear wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- How I would use Warren Buffett’s golden rules to build wealth with ASX shares
- Down 60%, are Cochlear shares now a bargain buy?
- Do experts rate BHP, Cochlear, and ResMed shares as buys, holds, or sells?
- Buy, hold, sell: 4DMedical, Cochlear, Westpac shares
- Why everyone selling Cochlear shares right now could regret it in 3 years
Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.